In summary, we demonstrated that Canagliflozin prevents peritoneal fibrosis induced by high glucose and improves peritoneal function by alleviating peritoneal hypoxia and inhibiting HIF-1α and TGF-β/p-Smad3 signaling pathways. Here, HIF1A is linked to Peritoneal Fibrosis.